Clinical Trials for COVID-19
In response to the global COVID-19 emergency, clinical trials assessing candidate interventions, including experimental treatments or vaccines as well as repurposed medicines, are emerging at an unprecedented rate.
To date, more than 1000 clinical trials, testing vaccines and other potential treatments (drugs, cell-based therapies and immunotherapies) have been registered to different international and national clinical trial registries.
This page intends to provide with an overview of the clinical trials currently launched worldwide for COVID-19, as collected within the COVID-19 clinical trials Registry (more details about the registry here).
We provide here with further analyses on these trials to include detailed information on the clinical trial phase, study design and results of the trials when available.
Information on the COVID-19 clinical trials
To date, 1093 clinical studies on COVID-19 were registered. Here following useful information about some clinical trials features.
Overview on the clinical trials status
The studies not included in thecategories below are classified as status unclear.
Not yet recruiting
Geographical distribution of the clinical trials
Asia: 351 studies (only 321 in China)
Europe: 135 studies
North America: 119 studies (105 in United States)
Middle East: 45 studies
South America: 27 studies
Australia: 3 studies
Clinical Trial phase
The study tests subtherapeutic doses (micro doses) on humans. They are planned to expedite the clinical evaluation of new molecular entities, allowing the demonstration of drug-target effects and assessment of pharmacokinetic-pharmacodynamic relationships in humans earlier in clinical development.
The study assesses the safety of the drug. It usually includes a small number of healthy volunteers (20 to 100). The study is designed to determine the effects of the drug on humans including how it is absorbed, metabolised, and excreted. This phase also investigates the side effects that occur as dosage levels are increased.
The study tests the efficacy of the drug and involves up to several hundred patients. This phase is also important to determine the correct dose to be experimented in the next phase.
The study involves several hundred to several thousand patients. This large-scale testing, which can last several years, provides with more understanding of the efficacy of the drug, the benefits and the range of possible adverse reactions.
After the marketing authorisation, the regulatory agencies keep on monitoring the efficacy and safety of the drug on the general population. Phase IV is based on post-marketing studies and on the spontaneous reports of adverse events from physicians, pharmacists and patients them self.